Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for CTX112 in Systemic lupus erythematosus. The expected timing is based on the latest available company guidance and may change.
12/9/24- Trial ongoing. 5/6/25- Provide update in mid-2025. 11/10/25:- Phase 1 trials of CTX112 in autoimmune diseases, including systemic lupus erythematosus, remain ongoing, and a broad program update is now expected by Q4 2025. 12/22/25:- Early Ph1 autoimmune basket data show deep B-cell depletion and SLE remission; further updates expected in H2 2026. 01/12/26:- SLE Ph1 shows ongoing remissions and B-cell depletion; broader autoimmune update still expected in H2 2026. 02/12/26:- Zugo-cel Ph1 autoimmune trials including SLE ongoing; company still guiding to autoimmune updates in H2 2026. 05/04/26:- Autoimmune baskets reached >14 patients and 10 sites; first two SLE patients maintain DORIS remission; updates H2 2026. 08/03/26:- SLE enrollment continues; zugo-cel autoimmune updates expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.